TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12098171

Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg twice a day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg twice a day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 62
Study: 10335002

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64) attended three education sessions, each of 90 minutes duration, spread over three successive weeks.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (n = 61) received usual care.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64) after three education sessions.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64)
Number of subjects: 125
Study: 8632365

Group type: EXPERIMENTAL
Intervention: Infrared tympanic thermometer (ITT)
Number of subjects: 4
Study: 2103687

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7443923

Group type: EXPERIMENTAL
Intervention: Variable Ratio (VR) feedback schedule
Number of subjects: 36

Group type: COMPARATOR
Intervention: Continuous feedback
Number of subjects: 36

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 36
Study: 6357892

Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate cream 0.05%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate cream 0.1%
Number of subjects: 40
Study: 31345717

Group type: EXPERIMENTAL
Intervention: Speckle tracking in the ME4C
Number of subjects: 25
Study: 29095407

Group type: COMPARATOR
Intervention: Non-SAE group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: SAE group
Number of subjects: 105
Study: 27113290

Group type: EXPERIMENTAL
Intervention: Paricalcitol (PCT, 2 μg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 24704050

Group type: EXPERIMENTAL
Intervention: CO2 group
Number of subjects: 35

Group type: COMPARATOR
Intervention: ICM group
Number of subjects: 35
Study: 21848948

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90mg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 20571804

Group type: EXPERIMENTAL
Intervention: 120 kVp and 1.8 ml/kg contrast agent (300 mgI/ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 80 kVp and 1.2 ml/kg contrast agent
Number of subjects: 80
Study: 18056526

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose
Number of subjects: 201

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/d maintenance dose
Number of subjects: 201

Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d maintenance dose
Number of subjects: 201
Study: 16096437

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/day; n=172)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Observation alone (n=168)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 340

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 340
Study: 12404032

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 14
Study: 10211917

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 31
Study: 7596218

Group type: EXPERIMENTAL
Intervention: Epalrestat (aldose reductase inhibitor), treated for one month
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untreated diabetic patients
Number of subjects: 3
Study: 2164706

Group type: EXPERIMENTAL
Intervention: Bovine rotavirus vaccine RIT 4237
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 573246

Group type: EXPERIMENTAL
Intervention: Nap group (16 subjects)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (16 subjects)
Number of subjects: 32
Study: 31811463

Group type: EXPERIMENTAL
Intervention: Elosan therapy (4-min sessions, twice/week for 28 days)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Elosan therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 39
Study: 31154088

Group type: EXPERIMENTAL
Intervention: WRN-PPNet (automatic segmentation method)
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art methods (control group)
Number of subjects: 0
Study: 28990439

Group type: EXPERIMENTAL
Intervention: Oral fennel (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 60
Study: 25675199

Group type: COMPARATOR
Intervention: Lowest homoarginine quartile (<1.40 μmol/L)
Number of subjects: 829
Study: 25629691

Group type: EXPERIMENTAL
Intervention: IC and high tissue loading
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IC and medium tissue loading
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IC and low tissue loading
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: No IC and high tissue loading
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: No IC and medium tissue loading
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: No IC and low tissue loading
Number of subjects: 6
Study: 23217651

Group type: EXPERIMENTAL
Intervention: Care by an emergency nurse practitioner (ENP)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Care by a doctor (DR)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Follow up health status using Short Form 12
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Adverse event rate (missed fractures or unplanned representations)
Number of subjects: 320
Study: 19770473

Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Telcagepant 150 mg
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Telcagepant 50 mg
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1294
Study: 18074473

Group type: EXPERIMENTAL
Intervention: Music intervention (slow movements of Mozart's piano sonatas)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 10
Study: 15274426

Group type: EXPERIMENTAL
Intervention: Thiopental (25 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Thiopental (50 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Thiopental (75 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Thiopental (100 mg)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Lidocaine (40 mg)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 137
Study: 11298311

Group type: EXPERIMENTAL
Intervention: Wire fixation
Number of subjects: 97

Group type: COMPARATOR
Intervention: Rigid fixation
Number of subjects: 97
Study: 9272794

Group type: EXPERIMENTAL
Intervention: Conditioning trials with verbal information to impede placebo expectancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 0
Study: 8319654

Group type: EXPERIMENTAL
Intervention: Chlorinated water (20 ppm, 1.5 L per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study: 3546223

Group type: EXPERIMENTAL
Intervention: Pre-treatment transurethral resection (TUR)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Definitive irradiation to the prostate (6500‐7000 cGy) and regional lymphatics (4500‐5000 cGy)
Number of subjects: 494
Study: 30633980

Group type: EXPERIMENTAL
Intervention: Lidocaine paracervical nerve block
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sham paracervical nerve block
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall procedure duration
Number of subjects: 95
Study: 27978579

Group type: EXPERIMENTAL
Intervention: Selumetinib 100 mg orally per day plus MK-2206 135 mg orally once per week
Number of subjects: 137

Group type: COMPARATOR
Intervention: mFOLFOX (oxaliplatin 85 mg/m2 intravenous and fluorouracil 2400 mg/m2 intravenous infusion over 46-48 hours)
Number of subjects: 137
Study: 25629634

Group type: EXPERIMENTAL
Intervention: Intrathecal naloxone (40 ng/24 h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intrathecal naloxone (400 ng/24 h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intrathecal morphine (control)
Number of subjects: 11
Study: 23948221

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment after 6 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (before CPAP)
Number of subjects: 12
Study: 21481064

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied on one side after FxCR treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal saline used as control on the contralateral side
Number of subjects: 25
Study: 18446364

Group type: EXPERIMENTAL
Intervention: Mixed-tasks condition with unpredictable task order
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-tasks condition with predictable task order
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task condition
Number of subjects: 0
Study: 16231341

Group type: EXPERIMENTAL
Intervention: Individual therapy (IND)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Group therapy (GRP)
Number of subjects: 86
Study: 15078380

Group type: EXPERIMENTAL
Intervention: Cardiac Analgesic Assessment Scale (CAAS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 69
Study: 10729392

Group type: EXPERIMENTAL
Intervention: Oleate (18:1 cis) meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Elaidate (18:1 trans) meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Palmitate (16:0) meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stearate (18:0) meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MCT (8:0+10:0) meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low fat meal (10 g fat)
Number of subjects: 16
Study: 8854774

Group type: COMPARATOR
Intervention: Arterial Embolization Chemotherapy (AEC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous Arterial Infusion Chemotherapy (CAIC)
Number of subjects: 32
Study: 1451218

Group type: EXPERIMENTAL
Intervention: Epidural morphine sulphate (4 mg in 10 ml saline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epidural saline (10 ml saline)
Number of subjects: 10
Study: 6091475

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g preoperatively)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 30684970

Group type: EXPERIMENTAL
Intervention: Low-dose hCG at the time of GnRH-agonist trigger (Group 1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low-dose hCG at the time of oocyte retrieval (Group 2)
Number of subjects: 71
Study: 29457493

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: No vitamin D supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study: 26742862

Group type: EXPERIMENTAL
Intervention: 27-gauge vitrectomy
Number of subjects: 66

Group type: COMPARATOR
Intervention: 25-gauge vitrectomy
Number of subjects: 66
Study: 24901088

Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings/day)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Low-soy diet (<3 servings/week)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Baseline (no specific diet mentioned)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Overall association across diets
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Within diet periods
Number of subjects: 256
Study: 22914593

Group type: EXPERIMENTAL
Intervention: Post-learning aerobic exercise (6 minutes at 70% VO2 max on a stationary bicycle)
Number of subjects: 0
Study: 19572092

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 17926827

Group type: EXPERIMENTAL
Intervention: Testosterone patches
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1095
Study: 15894699

Group type: EXPERIMENTAL
Intervention: Prenatal and postnatal milk supplementation
Number of subjects: 951

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 951
Study: 12296782

Group type: EXPERIMENTAL
Intervention: Atridox
Number of subjects: 47

Group type: COMPARATOR
Intervention: Elyzol Dental Gel
Number of subjects: 47

Group type: COMPARATOR
Intervention: PerioChip
Number of subjects: 47
Study: 10469093

Group type: EXPERIMENTAL
Intervention: FD Nd:YAG laser system 1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FD Nd:YAG laser system 2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FD Nd:YAG laser system 3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FD Nd:YAG laser system 4
Number of subjects: 40

Group type: COMPARATOR
Intervention: FD Nd:YAG lasers (all systems)
Number of subjects: 40
Study: 7555368

Group type: EXPERIMENTAL
Intervention: Dihydroetorphine hydrochloride (DHE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (blank)
Number of subjects: 90
Study: 1433772

Group type: EXPERIMENTAL
Intervention: Body positions and splints (alternative positions and splinting devices)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard supine position
Number of subjects: 144
Study: 6697637

Group type: EXPERIMENTAL
Intervention: Carteolol 0.5 to 60 mg daily
Number of subjects: 0
Study: 30995204

Group type: EXPERIMENTAL
Intervention: Adolescents with higher educational level
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Adolescents from higher socio-economic class
Number of subjects: 789

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 789
Study: 29596524

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS/treadmill exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS/treadmill exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS/treadmill exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20Hz rTMS/treadmill exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham conditions
Number of subjects: 12
Study: 26351400

Group type: EXPERIMENTAL
Intervention: Double row of sutures
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (single row of sutures)
Number of subjects: 36
Study: 23604641

Group type: EXPERIMENTAL
Intervention: Intensive stretching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supervised neglect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 0
Study: 21757183

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: pPCI
Number of subjects: 1572

Group type: COMPARATOR
Intervention: pPCI with system delay of 1 to 2 hours
Number of subjects: 1572

Group type: COMPARATOR
Intervention: pPCI with system delay >3 hours
Number of subjects: 1572
Study: 19685848

Group type: EXPERIMENTAL
Intervention: Lumbopelvic (LP) manipulation technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lumbar neutral gap (NG) manipulation technique
Number of subjects: 60
Study: 17117002

Group type: EXPERIMENTAL
Intervention: Hybrid functional electrical stimulation therapy on extensor carpi radialis longus and brevis, extensor digitorum communis, and extensor indicis proprius muscles, once or twice a week for 4 months after motor point blocks at the spastic finger flexor muscles
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study: 15065610

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 88 microg twice daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 440 microg twice daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 11704394

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102
Study: 9148533

Group type: EXPERIMENTAL
Intervention: Free fat transplantation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no free fat transplantation)
Number of subjects: 99
Study: 1586175

Group type: EXPERIMENTAL
Intervention: Exosurf (2 doses in 24 hours)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Exosurf (4 doses in 36 hours)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no Exosurf)
Number of subjects: 73
Study: 3841775

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg/die/p.o.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/die/p.o.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both interventions (Pirenzepine and Ranitidine)
Number of subjects: 20
Study: 31805923

Group type: EXPERIMENTAL
Intervention: Survey with standard drink term and pictorial guide
Number of subjects: 407

Group type: COMPARATOR
Intervention: Survey without standard drink term and pictorial guide
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Frequent drinkers among US students
Number of subjects: 407
Study: 29549681

Group type: EXPERIMENTAL
Intervention: Ultracision
Number of subjects: 250

Group type: COMPARATOR
Intervention: Ligasure
Number of subjects: 250
Study: 27335049

Group type: EXPERIMENTAL
Intervention: Crisaborole topical ointment, 2%, applied twice daily for 21 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle ointment, applied twice daily for 21 days
Number of subjects: 32
Study: 24094494

Group type: EXPERIMENTAL
Intervention: 12‐wk whole body vibration (WBV) intervention
Number of subjects: 50
Study: 23170964

Group type: EXPERIMENTAL
Intervention: Integrated community-based, intensive chronic condition management facilitated by Indigenous Health Workers (IHWs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 20860555

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 20
Study: 18515810

Group type: EXPERIMENTAL
Intervention: Threshold Assessment Grid (TAG) rating of mental health problem severity
Number of subjects: 408839

Group type: EXPERIMENTAL
Intervention: Post-referral primary care contact rates for intervention group GPs
Number of subjects: 408839
Study: 16114089

Group type: EXPERIMENTAL
Intervention: Butterbur extract (Ze 339; 8 mg total petasine; one tablet thrice‐daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Fexofenadine (Telfast 180; one tablet once‐daily)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 12187615

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 6

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 6
Study: 10526824

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 ng/ml
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 ng/ml
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7726352

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Morphine and Bupivacaine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Overall pattern in all patients
Number of subjects: 124
Study: 2247104

Group type: EXPERIMENTAL
Intervention: Nystatin (oral and vaginal)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (oral and vaginal)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All regimens (including placebo)
Number of subjects: 42
Study: 6451637

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg/day of 13‐cis‐retinoic acid
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/day of 13‐cis‐retinoic acid
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/day of 13‐cis‐retinoic acid
Number of subjects: 14
Study: 31682682

Group type: EXPERIMENTAL
Intervention: Group Medical Visits with Intensive Weight Management (WM/GMV)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Group Medical Visits (GMV)
Number of subjects: 263
Study: 31104138

Group type: EXPERIMENTAL
Intervention: Fuchs’ uveitis syndrome (FUS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy eyes (N)
Number of subjects: 21
Study: 28381530

Group type: COMPARATOR
Intervention: 0 g protein (control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5 g protein
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 10 g protein
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 15 g protein
Number of subjects: 35
Study: 25467562

Group type: EXPERIMENTAL
Intervention: SAFETY intervention
Number of subjects: 335

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 335
Study: 23823371

Group type: EXPERIMENTAL
Intervention: Automated vital sign collection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual vital sign collection
Number of subjects: 60
Study: 21429220

Group type: EXPERIMENTAL
Intervention: Powered device
Number of subjects: 102

Group type: COMPARATOR
Intervention: Manual device
Number of subjects: 102
Study: 19434489

Group type: EXPERIMENTAL
Intervention: Rapid-job-placement supported employment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Services-as-usual comparison conditions
Number of subjects: 0
Study: 18251439

Group type: EXPERIMENTAL
Intervention: Submerged upright position
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Submerged prone position
Number of subjects: 6
Study: 14719691

Group type: EXPERIMENTAL
Intervention: Template-based correction of brain MRI intensity distortion
Number of subjects: 0
Study: 11485708

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 mg twice daily)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 9674734

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) - continuous i.v. infusion (450 U/kg/24 h, n = 6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - enoxaparin, s.c. treatment (1.5 mg/kg, n = 12)
Number of subjects: 18